The purpose of this study is to evaluate the safety and effectiveness of the anticancer drug eribulin when added to standard chemotherapy given after surgery in women with early-stage breast cancer. Eribulin is a new chemotherapy drug approved for the treatment of advanced breast cancer that persists despite prior treatment, but its use for early-stage disease is considered investigational.
Eribulin, which is derived from a sea sponge, works by inhibiting microtubules (which provide scaffolding in cancer cells), leading to cell death. It is administered intravenously (by vein). In this study, eribulin will be given after one standard treatment for breast cancer with the drugs doxorubicin and cyclophosphamide.